Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.2 billion.

  • Astrazeneca's Short-term Investments rose 3621.32% to $2.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 3621.32%. This contributed to the annual value of $2.2 billion for FY2025, which is 3621.32% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Short-term Investments is $2.2 billion, which was up 3621.32% from $2.0 billion recorded in Q3 2025.
  • Astrazeneca's Short-term Investments' 5-year high stood at $2.2 billion during Q4 2025, with a 5-year trough of $83.0 million in Q4 2021.
  • Its 5-year average for Short-term Investments is $1.3 billion, with a median of $1.2 billion in 2022.
  • In the last 5 years, Astrazeneca's Short-term Investments crashed by 9023.41% in 2021 and then surged by 123770.49% in 2024.
  • Astrazeneca's Short-term Investments (Quarter) stood at $83.0 million in 2021, then surged by 187.95% to $239.0 million in 2022, then plummeted by 48.95% to $122.0 million in 2023, then skyrocketed by 1237.7% to $1.6 billion in 2024, then surged by 36.21% to $2.2 billion in 2025.
  • Its Short-term Investments stands at $2.2 billion for Q4 2025, versus $2.0 billion for Q3 2025 and $1.9 billion for Q2 2025.